+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Modular Facilities in Pharmaceutical and Biotechnology Market: Industry Trends and Global Forecasts, 2021-2030

  • PDF Icon


  • 302 Pages
  • April 2021
  • Region: Global
  • Roots Analysis
  • ID: 5359085


Industry stakeholders are regularly in pursuit of building strategic advantage(s) associated with product development and production processes; one of the ways to drive this is to establish flexible manufacturing capacity and deploy the associated infrastructure / facilities swiftly. Over the past few years, a large number of factors have converged to transform the facility construction paradigm within the pharmaceutical and biotechnology industries. The aforementioned factors include optimization of capital expenditure, reduction of construction timelines, integration of single-use technologies (e.g. single-use bioreactors), and the necessity to develop capabilities to support personalized medicine (driven by the need to address therapeutic requirements for rare / orphan clinical conditions). 

Pre-engineered, modular facilities have emerged as a versatile solution to the abovementioned problem statement. In fact, this approach has been demonstrated to be capable of addressing several challenges, such as weather-related concerns, shortage of skilled labor, labor contract constraints and delays in supply of raw materials. Furthermore, traditional production platforms require extensive investments, in terms of both capital and time. Such facilities also consist of built-in operating equipment attached to the facility substructure, necessitating extensive renovations for equipment upgrade and reconfiguration. On the other hand, in a modular approach, individual units of a facility and the required equipment (which is integrated into the facility design) are fabricated in factories away from the actual location of the facility. Moreover, the aforementioned facility templates are built to be flexible, with provisions for future expansion of area and capacity. This has been shown to significantly improve infrastructure development and installation time. For instance, in 2018, Janssen Pharmaceuticals, in collaboration with Legend Biotech, built a modular, commercial-scale facility, using a hybrid construction approach (which involved a combination of off-site and on-site construction); the edifice spanned 38,000 sq ft and was completed within a record time of nine months. It is also worth highlighting that the recent surge in demand for biopharmaceuticals due to COVID-19 pandemic has fueled the need for strategic changes in bioprocessing. In June 2020, Sanofi invested USD 554 million in the construction of a state-of-the-art modular vaccine production facility, in Neuville sur Saône, France, with the capacity to produce three to four vaccines simultaneously. 

Productivity in the conventional construction has been shown to never exceed 80%; this is usually attributed to logistical delays (transport of building material to the construction site) and inconsistent availability of manpower. On the other hand, in the modular construction approach, productivities of over 100% (up to 140%) have been reported. This can primarily be attributed to the fact that the latter method is executed in a controlled, fabrication shop environment and much of the fabrication process is automated (which eliminates the excessive reliance on manual labor), thereby, alleviating external risks and minimizing schedule overruns. Next generation construction methods are projected to evolve under the effect of current market dynamics. Several important developments in the pharmaceutical industry are influencing the design and construction of manufacturing facilities. Therefore, companies must retain the flexibility offered by contract manufacturers when they carry insourced projects in-house. Further, the advent of new modalities and next-generation drugs, such as cell and gene therapies and highly potent small molecule active pharmaceutical ingredients, which require specialized manufacturing facilities and equipment while avoiding cross-contamination and ensuring operator safety and protection, adds to need of platforms that are adaptable. Such trends, coupled to the increased pressure to improve efficiency, lower operating costs and acceleration of the drug development process, are considered to be the key drivers of the adoption of modular solutions. Moreover, biopharma industry continues to seek innovative ways of optimizing drug development costs and timelines. Off-site design and modularization demonstrate great potential to provide the industry with the agility to reduce the overall time to market for a particular product.

Scope of the Report

The “Modular Facilities in Pharmaceutical and Biotechnology Market by Type of Modular Construct (Hybrid Skid, Plug-and-Play, Skid-Mounted, Truckable and Others), Type of Construction Component (Base Building, Electrical System, Mechanical System, Process Equipment, Process Piping, Process Utilities and Other Components), Purpose of Facility (Aseptic Filling, Manufacturing, Research and Development and Others), Facility Area (Very Small, Small, Mid-Sized, Large and Very Large), Scale of Operation (Clinical and Commercial), Type of Industry (Pharmaceutical and Biotechnology), Type of Product (Biosimilars, Cell and Gene Therapies, Monoclonal Antibodies, Vaccines and Other Products), and by Key Geographical Regions (North America, Europe, Asia, Middle East and North Africa, Latin America and Rest of the World): Industry Trends and Global Forecasts, 2021-2030” report features an extensive study of the current market landscape and future potential of the players engaged in offering services for modular facility construction for biotechnology and pharmaceutical industries. The study presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain.

Amongst other elements, the report features:


  • A review of the market landscape of modular facilities along with information on their year of establishment, company size (small, mid-sized or large), location of headquarters (North America, Europe, Asia and rest of the world), geographical coverage, GMP compliance construction and type of industry served (pharmaceutical, biotechnology or others). It also includes details related to certifications obtained and COVID-19 related initiatives undertaken by modular service providers.
  • A review of the market landscape of modular cleanrooms along with information on their year of establishment, company size (small, mid-sized or large), location of headquarters (North America, Europe, Asia and rest of the world), type of industry served (pharmaceutical, biotechnology or others), type of modular cleanrooms (softwall and hardwall), type of modular cleanroom components (air handling units / HVAC system, fan filter units, laminar flow units, air showers, pass throughs, cleanroom furniture/furnishings, plumbing/piping, lighting/electricals). It also includes details related to regulatory approvals and certifications.
  • An analysis of the partnerships that have been inked by stakeholders in this domain, during the period between 2012 and 2021 (till January), covering facility construction agreements, cleanroom construction agreements, service alliances, service agreements and other relevant types of deals.
  • An analysis of modular projects undertaken across key geographical regions, featuring information on type of facility, facility area, most active manufacturers, most active clients, location of facility. We have provided a case study on JHL Biotech's KUBio biomanufacturing facility, which was constructed by GE Healthcare Life Sciences in China. It also includes information on modular projects received by key pharma/biotech players based on location, type and area of facility.
  • An insightful analysis on facility construction trends in the pharmaceutical industry for the last five years, highlighting facility construction projects established by top 20 pharma / biotech players, along with information on their number of facilities, type of facility, purpose, investments made in modular projects, area of facility and location of headquarters.
  • Elaborate profiles of key players that provide a wide range of modular manufacturing solutions to pharmaceutical and biotechnology industries. Each profile features a brief overview of the company (including information on year of establishment, number of employees, location of headquarters and key members of the executive team), details related to modular facility-focused services, modular projects, recent developments and an informed future outlook.
  • A review of emerging trends, including the combination of single-use technologies / continuous processing technologies with modular facilities, the shift to using smaller, multi-purpose modular facilities, and technological advancements in modular construction processes.
  • A detailed discussion on the various growth drivers, such as the development of personalized medicines, biosimilars, orphan drugs and the anticipated increase in the adoption of modular solutions in emerging markets by pharmaceutical/biopharmaceutical CMOs. It also highlights trends, such as expansion of existing facilities and adoption of modular facilities by emerging start-ups and small companies.

One of the key objectives of this report was to estimate the existing market size and the future growth potential within the pharmaceutical/biotechnology modular manufacturing market. We have developed informed estimates on the financial evolution of the market, over the period 2021-2030. The report also provides details on the likely distribution of the current and forecasted opportunity across [A] type of modular construct (hybrid skid, plug-and-Play, skid-mounted, truckable and others), [B] type of construction component (base building, electrical system, mechanical system, process equipment, process piping, process utilities, and other components), [C] purpose of facility (aseptic filling, manufacturing, research and development, and others), [D] facility area (very small, small, mid-sized, large and very large plants), [E] scale of operation (clinical and commercial), [F] type of industry (pharmaceutical and biotechnology), [G] type of product (biosimilars, cell and gene therapies, monoclonal antibodies, vaccines, and other products) and [H] key geographical regions (North America, Europe, Asia, Middle East and North Africa, Latin America and rest of the world). In order to account for future uncertainties and to add robustness to our forecast model, we have provided three scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth. 

The opinions and insights presented in the report were also influenced by discussions held with multiple stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals (in alphabetical order):

Alan de Zayas (Modular Building Manufacturing and Construction Team, Avon Modular Construction)
François Abiven (Executive Vice-President Global Business Unit BLS and Luca Mussati Vice President, Pharma and Biotech Life Sciences, Exyte)
Maik Jornitz (President and Chief Executive Officer, G-CON Manufacturing)
Pär Almhem (President, Modwave)
Sulogna Roy (Ex Sales Manager, Zeton)
Vernon Solomon (Specialist in Modular Design for Cleanrooms and Close Tolerance Temperature and Humidity Control, Environmental Systems Corporation)

All actual figures have been sourced and analyzed from publicly available information forums. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered


  • Who are the key service providers engaged in domain of modular construction? What are the current trends fueling the adoption of modular construction solutions in the pharma/biotech industries?
  • Which key regions are targeted by pharma/biotech companies for expanding their existing facilities and capabilities?
  • What type of product lines are actively supported by integrated modular solutions in facility design and construction?
  • What are the recent initiatives undertaken by modular manufacturers in order to overcome the challenges related to the COVID-19 pandemic? 
  • Which regions are the current hubs for modular construction service providers?
  • Which partnership models are most commonly adopted by stakeholders engaged in this industry?
  • How is the current and future opportunity likely to be distributed across key market segments?

Table of Contents

1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

3.1. Chapter Overview
3.2. Historical Background
3.3. The Concept of Modularization
3.3.1. Types of Modular Constructs
3.3.2. Modular Construction Process
3.4. Modular Construction in the Pharmaceutical Industry
3.4.1. Advantages of Modular Construction in the Pharmaceutical Industry
3.4.2. Modular Pharmaceutical Cleanrooms Cleanroom Classifications and Current Standards Regulations and Standards Concerning Modular Cleanroom Construction
3.5. Advantages of Modular Cleanrooms
3.6. Challenges and Future Prospects

4.1. Chapter Overview
4.2. Modular Facility Manufacturers: Overall Market Landscape
4.2.1 Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Geographical Coverage
4.2.5. Analysis by Geographical Coverage and GMP Compliance
4.2.6. Analysis by Type of Industry Served
4.2.7. Analysis by Geographical Coverage and Type of Industry Served
4.2.8. Historical and Current Market Landscape Trend Analysis Analysis by Company Size, Geographical Coverage and Type of Industry Served
4.2.9. Quality Certifications
4.3. Modular Facility Manufacturers: COVID-19-related Initiatives

5.1. Chapter Overview
5.2. Modular Cleanroom Providers: Overall Market Landscape
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size
5.2.3. Analysis by Location of Headquarters
5.2.4. Analysis by Type of Industry Served
5.2.5. Analysis by Type of Modular Cleanroom Offered
5.2.6. Analysis by Type of Industry Served and Type of Modular Cleanrooms
5.2.7. Analysis by Type of Cleanroom Component Offered
5.2.8. Analysis by Type of Modular Cleanroom and Cleanroom Component Offered
5.2.9. Analysis by Type of Industry Served and Type of Cleanroom Component Offered
5.2.10. Analysis by Location of Headquarters and Type of Industry Served
5.2.11. Analysis by Location of Headquarters, Type of Industry Served and Type of Modular Cleanroom
5.2.12. Regulatory Approvals and Certifications

6.1. Chapter Overview
6.2. Cytiva
6.2.1. Company Overview
6.2.2. Modular Facility-related Services
6.2.3. Modular Projects
6.2.4. Recent Developments and Future Outlook
6.3. G-CON Manufacturing
6.3.1. Company Overview
6.3.2. Modular Facility-related Services
6.3.3. Modular Projects
6.3.4. Recent Developments and Future Outlook
6.4. Pharmadule Morimatsu
6.4.1. Company Overview
6.4.2. Modular Facility-related Services
6.3.3. Modular Projects
6.3.4. Recent Developments and Future Outlook
6.5. NNE
6.5.1. Company Overview
6.5.2. Modular Facility-related Services
6.5.3. Modular Projects
6.5.4. Recent Developments and Future Outlook
6.6. IPM Technologies
6.6.1. Company Overview
6.6.2. Modular Facility-related Services
6.6.3. Modular Projects
6.6.4. Recent Developments and Future Outlook
6.7. KeyPlants
6.7.1. Company Overview
6.7.2. Modular Facility-related Services
6.7.3. Modular Projects
6.7.4. Recent Developments and Future Outlook
6.8. Germfree Laboratories
6.8.1. Company Overview
6.8.2. Modular Facility-related Services
6.8.3. Modular Projects
6.8.4. Recent Developments and Future Outlook
6.9. ModuleCO Pharma
6.9.1. Company Overview
6.9.2. Modular Facility-related Services
6.9.3. Modular Projects
6.9.4. Recent Developments and Future Outlook

7.1. Chapter Overview
7.2. Types of Partnership Models
7.3. Modular Facility Providers: Partnerships and Collaborations
7.3.1. Analysis by Year of Partnership
7.3.2. Analysis by Type of Partnership Analysis by Year and Type of Partnership
7.3.3. Analysis by Type of Product Analysis by Type of Partnership and Type of Product
7.3.4. Analysis by Type of Modular Facility Analysis by Type of Product and Type of Modular Facility
7.3.5. Most Active Players: Analysis by Number of Partnerships
7.3.6. Regional Analysis Analysis by Location of Headquarters of Partner Analysis by Location of Facility Analysis by Type of Partnership and Location of Facility Analysis by Type of Product and Location of Facility
7.3.7. Intercontinental and Intracontinental Partnerships Country-wise Distribution Regional Distribution Analysis by Type of Partnership, Type of Product, Location of Facility and Type of Agreement

8.1. Chapter Overview
8.2. Modular Facility Projects Undertaken in the Pharmaceutical / Biotechnology Industry
8.3. Analysis by Type of Facility
8.4. Analysis by  Facility Area
8.5. Analysis by Type of Facility and Facility Area
8.6. Most Active Manufacturers: Analysis by Number of Projects Delivered
8.7. Most Active Clients: Analysis by Number of Projects Received
8.8. Analysis by Location of Facility
8.9. Analysis by Client and Location of Facility
8.10. Modular versus Conventional Construction Methods
8.11. Return on Investment
8.12. Case Study: Facility Based on KUBio Platform
8.12.1. GE Healthcare’s KUBio Platform: Overview
8.12.2. JHL Biotech’s KUBio Modular Project in China: Overview and Construction Details

9.1. Chapter Overview
9.2. Facility Construction Projects Undertaken in the Pharmaceutical / Biotechnology Industry (Top 20 Companies): Historical Data, 2016-2020 (Till December)
9.2.1. Analysis by Number of Facilities
9.2.2. Analysis by Type of Facility
9.2.3. Analysis by Purpose of Facility
9.2.4. Analysis by Investment
9.2.5. Analysis by Facility Area
9.2.6. Analysis by Location of Headquarters

10.1. Chapter Overview
10.2. Forecast Methodology and Key Assumptions
10.3. Modular Facilities Market, 2021-2030
10.4. Modular Facilities Market: Distribution by Type of Modular Construct
10.4.1. Modular Facilities Market for Hybrid Skid Modular Construct, 2021-2030
10.4.2. Modular Facilities Market for Plug-and-Play Modular Construct, 2021-2030
10.4.3. Modular Facilities Market for Skid-Mounted Modular Construct, 2021-2030
10.4.4. Modular Facilities Market for Truckable Modular Construct, 2021-2030
10.4.5. Modular Facilities Market for Others, 2021-2030
10.5. Modular Facilities Market: Distribution by Type of Construction Component
10.5.1. Modular Facilities Market for Base Building, 2021-2030
10.5.2. Modular Facilities Market for Electrical System, 2021-2030
10.5.3. Modular Facilities Market for Mechanical System, 2021-2030
10.5.4. Modular Facilities Market for Process Equipment, 2021-2030
10.5.5. Modular Facilities Market for Process Piping, 2021-2030
10.5.6. Modular Facilities Market for Process Utilities, 2021-2030
10.5.7. Modular Facilities Market for Other Components, 2021-2030
10.6 Modular Facilities Market: Distribution by Purpose of Facility
10.6.1. Modular Facilities Market for Aseptic Filling, 2021-2030
10.6.2. Modular Facilities Market for Manufacturing, 2021-2030
10.6.3. Modular Facilities Market for Research and Development, 2021-2030
10.6.4. Modular Facilities Market for Others, 2021-2030
10.7. Modular Facilities Market: Distribution by Facility Area
10.7.1. Modular Facilities Market for Very Small Plants, 2021-2030
10.7.2. Modular Facilities Market for Small Plants, 2021-2030
10.7.3. Modular Facilities Market for Mid-Sized Plants, 2021-2030
10.7.4. Modular Facilities Market for Large Plants, 2021-2030
10.7.5. Modular Facilities Market for Very Large Plants, 2021-2030
10.8. Modular Facilities Market: Distribution by Scale of Operation
10.8.1. Modular Facilities Market for Clinical Operations, 2021-2030
10.8.2. Modular Facilities Market for Commercial Operations, 2021-2030
10.9. Modular Facilities Market: Distribution by Type of Industry
10.9.1. Modular Facilities Market for Pharmaceutical, 2021-2030
10.9.2. Modular Facilities Market for Biotechnology, 2021-2030
10.10. Modular Facilities Market: Distribution by Type of Product
10.10.1. Modular Facilities Market for Biosimilars, 2021-2030
10.10.2. Modular Facilities Market for Cell and Gene Therapies, 2021-2030
10.10.3. Modular Facilities Market for Monoclonal Antibodies, 2021-2030
10.10.4. Modular Facilities Market for Vaccines, 2021-2030
10.10.5. Modular Facilities Market for Other Products, 2021-2030
10.11. Modular Facilities Market: Distribution by Key Geographical Regions
10.11.1. Modular Facilities Market for North America, 2021-2030
10.11.2. Modular Facilities Market for Europe, 2021-2030
10.11.3. Modular Facilities Market for Asia, 2021-2030
10.11.4. Modular Facilities Market for Middle East and North Africa, 2021-2030
10.11.5. Modular Facilities Market for Latin America, 2021-2030
10.11.6. Modular Facilities Market for Rest of the World, 2021-2030
10.12. Concluding Remarks

11.1. Chapter Overview
11.2. The Pharmaceutical Industry is Rapidly Adopting Smaller Modular Facilities
11.3. Integration of Single Use Technologies with Modular Facilities Offers Flexibility and Economic Benefits
11.4. Continuous Processing Technologies Offer Added Advantages to the Modular Approach
11.5. Modular Facilities are Integrated with Advanced Technology Emphasizing Improved Productivity
11.6. The Market is Abuzz with Partnership Activity as Service Providers Form Strategic Alliances to Expand their Portfolios

12.1. Chapter Overview
12.2. The Modular Approach is Popular Amongst Start-Ups and Small Companies
12.3. In Order to Accelerate Time to Market and Stay Competitive, Several Biosimilar Manufacturers are Expected to Install Modular Facilities
12.4. Addressing the Niche Requirements, Orphan Indications Offer Additional Opportunities for Modular Facility Manufacturers
12.5. Emerging Regions are Likely to be Attractive Markets for Stakeholders in the Long Term
12.6. Expansions of Existing Facilities Using Modular Solutions are Projected to Increase Significantly
12.7. Several Contract Manufacturing Organizations have Adopted Modular Solutions

13.1. Chapter Overview
13.2. Key Takeaways

14.1. Chapter Overview
14.2. G-CON Manufacturing
14.2.1. Company Snapshot
14.2.2. Interview Transcript: Maik Jornitz, Chief Executive Officer
14.3. Modwave
14.3.1. Company Snapshot
14.3.2. Interview Transcript: Pär Almhem, President
14.4. Environmental Systems Corporation
14.4.1. Company Snapshot
14.4.2. Interview Transcript: Vernon Solomon, President
14.5. Exyte
14.5.1. Company Snapshot
14.5.2. Interview Transcript: François Abiven, Executive Vice President, Luca Mussati, Vice President, Technology and Innovation
14.6. Avon Modular Construction
14.6.1. Company Snapshot
14.6.2. Interview Transcript: Alan de Zayas, Modular Building Manufacturing and Construction Team
14.7. Zeton
14.7.1. Company Snapshot
14.7.2. Interview Transcript: Sulogna Roy, Sales Manager / Project Manager


Companies Mentioned

  • 209Technologies 
  • 3P Biopharmaceuticals
  • A.D Clean Rooms (Katz Group)
  • Labyrinth BioPharma (Formerly known as AB Biotechnology)
  • Abbott
  • AbbVie
  • ABN Cleanroom Technology
  • Abtech
  • ACH Engineering
  • Acumen Technology
  • AES Clean Technology
  • Air Micron Cleantech
  • Aircare Projects 
  • Airgas
  • Airology
  • Airplan
  • Airtech Systems
  • Aizon
  • Ajinomoto North America
  • Albian Group
  • Alembic Pharmaceuticals 
  • Allied Cleanrooms
  • AM Technical Solutions
  • AME For Industry 
  • American Cleanroom Systems
  • Amgen
  • Amicron Cleantech
  • Angstrom Technology 
  • AqVida
  • Ardmac
  • Asgard Cleanroom Solutions
  • AstraZeneca
  • AveXis
  • Avon Modular
  • AWS Bio-Pharma Technologies
  • Axenic Systems
  • Bangalore Air Tech Solution
  • Bassaire 
  • Baxter
  • Bayer
  • BC Technology
  • BeiGene
  • Belcher Equipment
  • Bigneat
  • BioCon Solutions
  • Biogen
  • Biologics Modular 
  • Bioscience Institute
  • Bladeroom
  • Bode Equipment
  • Boehringer Ingelheim
  • Brammer Bio
  • Bristol Myers Squibb
  • Butler Manufacturing
  • Cambridge Cleanroom
  • CCRM
  • C-Cube
  • Cell and Gene Therapy Catapult
  • CID Associates
  • Cipharm
  • Clean Air Flow
  • Clean Air Products
  • Clean Air Systems
  • Clean Air Technology
  • Clean Modules
  • Clean Room Depot 
  • Clean Rooms International
  • Clean Rooms Plus
  • Clean Zone Technology 
  • CleanAir Solutions
  • Cleanetics
  • Cleanroom Ceiling Systems (A division of Varni Enterprises)
  • Cleanroom Equipment
  • Cleanroom Results
  • Cleanroom Solutions
  • Cleanroom Synergy 
  • Cleanrooms Australia 
  • Cleanrooms By United
  • Cleanrooms Containments
  • Clean Rooms West
  • CleanZones
  • ClearSphere
  • Clestra Cleanroom 
  • Codiak BioSciences
  • Commercial Structures Corporation
  • Connect 2 Cleanrooms
  • CONSAB International 
  • CRB
  • Cubic Pharmaceuticals
  • Cyberfreight Pharma Logistics
  • Cytiva
  • Daldrop
  • Design Filtration Microzone
  • DPR Construction
  • E-Pack Polymers
  • Ebtech Industrial Modular Building Solutions 
  • EirGen Pharma
  • Eli Lilly
  • Emergent BioSolutions
  • Enbloc
  • Envair Electrodyne
  • Environmental Systems Corporation (ESC)
  • Erytech Pharma
  • Exyte (A subsidiary of M+W Group)
  • Expression Therapeutics
  • Ferring Pharmaceuticals
  • Filtration Technology 
  • Firmament Technology
  • Firs Bioengineering
  • Florida Cleanroom Systems
  • Flowstar Corporation 
  • Fluor
  • Fraunhofer Project Centre 
  • Galderma
  • G-CON Manufacturing
  • GenCure
  • Genentech
  • Gerbig Engineering Company
  • Germfree 
  • Gilead Sciences
  • GlaxoSmithKline
  • GMP Technical Solutions
  • GMPMax Pharma
  • Green Carrier Consultancy and Tech Solutions
  • Guardtech Cleanrooms
  • Halco Products
  • HAZE comfort
  • Healthcare Diagnostics 
  • Hectra Enviro Systems
  • Hemair Systems
  • HEMCO Corporation
  • HEPAire Products Corporation
  • Hermetel Oy
  • Hexakore
  • Hodess Construction
  • HOK
  • Holden
  • Hume Group MC
  • Huntair
  • Iberconcept
  • Innovative Cleanroom Technologies
  • Ingelyt
  • Innclose
  • North Central Instruments (Formerly known as Innotech Products)
  • Instaspace
  • Instituto Butantan
  • Integrated Cleanroom Technologies 
  • IPM Technologies
  • IPS
  • IsoTech Design
  • Jacobs
  • JHL Biotech
  • Johnson & Johnson
  • Just-Evotec Biologics
  • KABTech Corporation
  • KeyPlants
  • Kingspan
  • KTEC Cleanroom Systems
  • L7 Informatics
  • Labard Instruchem
  • Labover
  • LabRum
  • Labworks International
  • Lasco Services
  • Legend Biotech
  • Lennox Clean Air Technologies
  • Libbs Farmacêutica
  • Liberty Industries
  • LifeAire Systems
  • LM Air Technology
  • Longden Company
  • Lonza
  • La Salle Blanche
  • M+W Group
  • Mach-Aire
  • MAK Clean Air Systems
  • Mars Sterile Solutions
  • Mayo Clinic
  • McLennan & Company 
  • M Davis & Sons
  • MDI
  • Medical Air Technology
  • Medicus Mundi
  • Medipharma
  • Merck
  • Merit Holdings
  • Modubuild
  • Modular Cleanrooms 
  • Modular Panel Systems
  • ModuleCo Pharma
  • Modulus Cleanrooms
  • Monmouth Scientific 
  • MRC Systems
  • Merck Sharp & Dohme
  • MTX Contracts
  • Nano Clean
  • National Institutes of Health (NIH)
  • National Partitions
  • NGS Cleanroom Solutions
  • Nicomac
  • NNE
  • Norwood Group
  • Novartis
  • Novo Nordisk
  • Octapharma
  • Omrix Biopharmaceuticals
  • Ori Biotech
  • Oxford BioMedica
  • Pacific Environmental Technologies
  • Pall Biotech
  • Panel Built 
  • Parteco
  • PC Company
  • Penn Medicine
  • Pentec Health
  • Perotech Sciences
  • Pfizer
  • Pharmacon
  • Pharmadule (Acquired by Morimatsu Group)
  • Plascore
  • PortaFab
  • Porta-King Building Systems
  • Power And Motion
  • Precise Engineering Design
  • Precision Air Technology
  • Precision Cleanrooms
  • ProCleanroom
  • Purever Tech
  • QleanAir Scandinavia
  • Regeneron
  • Replenish
  • Riddhi Metals
  • Rinac India
  • Robert Soper
  • Roche
  • Rubius Therapeutics
  • Sanaria
  • Sanofi
  • Sapphire Cleanrooms 
  • Saudi Bio
  • Schering-Plough
  • Schilling Engineering
  • SGS
  • Shanghai HJ Modular Cleanroom
  • Shanghai Junshi Biosciences
  • Shelving + Rack Systems 
  • Siemens
  • Simplex Isolation Systems
  • Skylark Engineering Technologies
  • SLAC
  • Span Construction and Engineering
  • Speed Space
  • Srprefabs Modular Cleanroom
  • Starrco 
  • Stefatos
  • Steriltech
  • Stodec Products
  • Stragen Pharma
  • Strike Bio
  • Swedish Modules
  • Syntec Airflow System
  • SZ Airkey Environmental Tech & Eng
  • Takeda
  • Technical Air Products
  • Ted Thorsen Material Handling
  • Telstar Life Science Solutions
  • Terra Universal 
  • Zhejiang Teruisi Pharmaceutical 
  • Teva Pharmaceutical Industries
  • The Softwall Shop 
  • Tocci Building
  • Travis Clean Air (TCS)
  • Triumph Modular
  • Tudela International
  • Ultrapure Technology 
  • Unikelvin Ventures
  • United Partition Systems
  • Univercells
  • Unibio
  • University of Tennessee Health Science Center
  • Vanguard Modular Building Systems
  • Vanrx Pharmasystems (Acquired by Cytiva)
  • Veltek Associates
  • Vernick 
  • VRP Cleanroom Systems
  • W.W. Cannon
  • Weaver Technologies
  • Westbury Cleanrooms
  • Western Environmental Corporation
  • WH Engineering
  • Whitenair Technologies
  • WHP Engineering
  • WuXi Vaccines
  • XBiotech 
  • Xytel
  • YRS Enterprises
  • Zeton
  • Ziccum